FocalTherics (EDAP TMS SA) reported preliminary unaudited Q2 2026 financial results for its continuing HIFU operations, announcing revenue between $12.7 million and $13.2 million, a 34-39% increase year-over-year, with gross margins of 54-56%. The company classified its ESWL and Distribution segments as discontinued operations effective Q2 2026 due to a planned strategic exit. Cash, cash equivalents, and short-term investments totaled $21.5 million as of June 30, 2026. Additionally, the company highlighted commercial momentum with 13 Focal One system sales in the quarter and an installed base of 184 systems globally. The firm is advancing its robotic HIFU platform into new indications including benign prostatic hyperplasia (BPH) and deep infiltrating endometriosis, having initiated a limited commercial launch for endometriosis in Europe under its CE mark. EDAP TMS SA develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology.
